ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2456

High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2457

Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Abstract Number: 2458

Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2459

Use of Nailfold Capillaroscopy as a Predictor of Cardiovascular Events and Mortality in Systemic Sclerosis
Abstract Number: 2460

Severe Gastrointestinal Involvement in Systemic Sclerosis: A New “Transversal” Subset of Disease to Be Prioritised for Intervention Trials
Abstract Number: 2461

Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy
Abstract Number: 2462

A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis
Abstract Number: 2463

Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization
Abstract Number: 2464

Thymic Size Longitudinal Changes on Chest High-resolution Computed Tomography After Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2465

Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR
Abstract Number: 2466

Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Abstract Number: 2467

Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Abstract Number: 2468

Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease
Abstract Number: 2469

Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Abstract Number: 2470

Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].